Advertisement
| dual beta lactam therapy: Oral Cephalosporins Robert C. Moellering, 1995 This volume provides an excellent survey of the chemistry, microbiology, pharmacology and clinical use of the oral cephalosporins in general and the newer agents in particular. The cephalosporins have long provided satisfactory treatment for many disorders without causing serious side effects; and over the past fifty years forms with different antimicrobial, pharmacologic and toxicologic properties have been developed. Despite the broad spectrum of their activity against a large variety of gram-positive and gram-negative bacteria, the third-generation oral cephalosporins including the prodrug esters do not work against Pseudomonas aeruginosa, methicillin-resistant staphylococci, enterococci or Bacteroides species. Many, however, are suitable for treating infections of the respiratory and urinary tracts and of the skin and its structure, as well as certain sexually-transmitted diseases. Authors consider other possible uses, against multi-resistant Enterobacteriaceae for instance, but also point out the limitations of the oral cephalosporins. For those working in the fields of infectious disease, bacteriology, chemotherapy, pharmaceutics and pharmacokinetics, this book is a valuable source of authoritative information. |
| dual beta lactam therapy: Penicillins and Cephalosporins Robert B. Morin, Marvin Gorman, 2014-05-10 Chemistry and Biology of ?-Lactam Antibiotics, Volume 1: Penicillins and Cephalosporins provides information pertinent to the study of antibiotics containing the ?-lactam moiety. This book discusses the occurrence of a group of ?-lactam antibiotics structurally related to cephalosporin C. Organized into five chapters, this volume begins with an overview of the mechanism of action of ?-lactam antibiotics that caused many microbiologists to develop screening tools for the detection of the ?-lactam moiety. This text then discusses the discovery of the nocardicins, the thienamycins, and olivanic acids. Other chapters provide a summary of the essential penicillin sulfoxide chemistry that gave rise to many compounds. This book discusses as well the ability of chemists to predict the level of biological activity of a compound from knowledge of its structure through theoretical and physicochemical studies. The final chapter deals with quantitative structure–activity relationships. This book is a valuable resource for microbiologists, chemists, and scientists. |
| dual beta lactam therapy: Severe Community Acquired Pneumonia Jordi Rello, Kenneth V. Leeper, Kenneth Leeper, 2001-06-30 Severe Community Acquired Pneumonia is a book in which chapters are authored and the same topics discussed by North American and European experts. This approach provides a unique opportunity to view the different perspectives and points of view on this subject. Severe CAP is a common clinical problem encountered in the ICU setting. This book reviews topics concerning the pathogenesis, diagnosis and management of SCAP. The discussions on the role of alcohol in severe CAP and adjunctive therapies are important topics that further our understanding of this severe respiratory infection. |
| dual beta lactam therapy: Antimicrobial Stewardship Céline Pulcini, Onder Ergonul, Fusun Can, Bojana Beović, 2017-04-05 Antimicrobial Stewardship (AMS), Volume Two includes the experience of ESGAP workshops and courses on antibiotic stewardship since 2012. It combines clinical and laboratory information about AMS, with a focus on human medicine. The ESCMID study group on antibiotic policies (ESGAP) is one of the most productive groups in the field, organizing courses and workshops. This book is an ideal tool for the participants of these workshops. With short chapters (around 1500 words) written on different topics, the authors insisted on the following points: A 'hands on', practical approach, tips to increase success, a description of the most common mistakes, a global picture (out- and inpatient settings, all countries) and a short list of 10-20 landmark references. - Focuses on the most recent antimicrobial stewardship strategies - Provides a detailed description of laboratory support - Offers a balanced synthesis of basic and clinical sciences for each individual case, presenting clinical courses of the cases in parallel with the pathogenesis and detailed microbiological information for each infection - Describes the prevalence and incidence of the global issues and current therapeutic approaches - Presents the measures for infection control |
| dual beta lactam therapy: Anthrax in Humans and Animals World Health Organization, 2008 This fourth edition of the anthrax guidelines encompasses a systematic review of the extensive new scientific literature and relevant publications up to end 2007 including all the new information that emerged in the 3-4 years after the anthrax letter events. This updated edition provides information on the disease and its importance, its etiology and ecology, and offers guidance on the detection, diagnostic, epidemiology, disinfection and decontamination, treatment and prophylaxis procedures, as well as control and surveillance processes for anthrax in humans and animals. With two rounds of a rigorous peer-review process, it is a relevant source of information for the management of anthrax in humans and animals. |
| dual beta lactam therapy: Antimicrobial Therapy I , 1995 |
| dual beta lactam therapy: Medical Pharmacology and Therapeutics E-Book Derek G. Waller, Tony Sampson, 2013-08-07 This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice. Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examples Includes more on genetic issues Drug tables made more concise to make information more accessible Fully updated to reflect current clinical practice |
| dual beta lactam therapy: Continuous Renal Replacement Therapy John A. Kellum, Rinaldo Bellomo, Claudio Ronco, 2016 Continuous Renal Replacement Therapy provides concise, evidence-based, bedside guidance for the management of critically ill patients with acute renal failure, offering quick reference answers to clinicians' questions about treatments and situations encountered in daily practice. |
| dual beta lactam therapy: Infective Endocarditis Arman Kilic, 2021-11-28 Infective Endocarditis: A Multidisciplinary Approach provides a comprehensive review of infective endocarditis and covers the entire spectrum of medical care for these challenging patients. It covers the ever-increasing scope of the problem, including epidemiology, as well as diagnostic work-up, microbiology, medical therapy, and surgical therapy for this disease. The book also addresses the opioid epidemic and rising infective endocarditis incidence in this population. Each type of practitioner can use this book as a definitive resource in reviewing aspects of care related to the endocarditis patient. This book will also serve as an updated resource to provide recent evidence regarding the management of these patients, as well as author perspectives and approaches to tackling the often complex and challenging issues revolving around care of the endocarditis patient. This is an essential reference and an authoritative source for infective endocarditis and provide physicians, nurses, social workers, and everyone who is routinely involved in the care of these patients. - Provides a thorough, yet concise review from a multidisciplinary perspective on the work-up and management of infective endocarditis - Presents updated reviews on evidence and current guidelines for treating patients with infective endocarditis - Provides discussion on controversial aspects of management, both medical and ethical |
| dual beta lactam therapy: Persistent Bacterial Infections James P. Nataro, Martin J. Blaser, Susanna Cunningham-Rundles, 2000 An examination of persistent bacterial infections in the light of ecological and evolutionary principles. - Focuses on the principles of parasitism and commensalism and our ability to distinguish the two states. - Explores the ways in which persistent infections differ from acute, self-limiting bacterial infections and how both differ from the nonpathogenic commensal state. - Addresses coevolution, host adaptation, natural selection, and other fundamental biological principles. - Serves as a resource for investigators and advanced students in the field of bacterial pathogenesis. |
| dual beta lactam therapy: Antimicrobial Drug Resistance Douglas Mayers, 2009-07-14 This ? rst edition of Antimicrobial Drug Resistance grew out of a desire by the editors and authors to have a comprehensive resource of information on antimicrobial drug resistance that encompassed the current information available for bacteria, fungi, protozoa and viruses. We believe that this information will be of value to clinicians, epidemiologists, microbiologists, virologists, parasitologists, public health authorities, medical students and fellows in training. We have endeavored to provide this information in a style which would be accessible to the broad community of persons who are concerned with the impact of drug resistance in our cl- ics and across the broader global communities. Antimicrobial Drug Resistance is divided into Volume 1 which has sections covering a general overview of drug resistance and mechanisms of drug resistance ? rst for classes of drugs and then by individual microbial agents including bacteria, fungi, protozoa and viruses. Volume 2 addresses clinical, epidemiologic and public health aspects of drug resistance along with an overview of the conduct and interpretation of speci? c drug resistance assays. Together, these two volumes offer a comprehensive source of information on drug resistance issues by the experts in each topic. |
| dual beta lactam therapy: WHO Recommendations for Prevention and Treatment of Maternal Peripartum Infections World Health Organization, 2016-02-12 The goal of the present guideline is to consolidate guidance for effective interventions that are needed to reduce the global burden of maternal infections and its complications around the time of childbirth. This forms part of WHO's efforts towards improving the quality of care for leading causes of maternal death especially those clustered around the time of childbirth in the post-MDG era. Specifically it presents evidence-based recommendations on interventions for preventing and treating genital tract infections during labour childbirth or puerperium with the aim of improving outcomes for both mothers and newborns. The primary audience for this guideline is health professionals who are responsible for developing national and local health protocols and policies as well as managers of maternal and child health programmes and policy-makers in all settings. The guideline will also be useful to those directly providing care to pregnant women including obstetricians midwives nurses and general practitioners. The information in this guideline will be useful for developing job aids and tools for both pre- and inservice training of health workers to enhance their delivery of care to prevent and treat maternal peripartum infections. |
| dual beta lactam therapy: Red Book Atlas of Pediatric Infectious Diseases American Academy of Pediatrics, 2007 Based on key content from Red Book: 2006 Report of the Committee on Infectious Diseases, 27th Edition, the new Red Bookr Atlas is a useful quick reference tool for the clinical diagnosis and treatment of more than 75 of the most commonly seen pediatric infectious diseases. Includes more than 500 full-color images adjacent to concise diagnostic and treatment guidelines. Essential information on each condition is presented in the precise sequence needed in the clinical setting: Clinical manifestations, Etiology, Epidemiology, Incubation period, Diagnostic tests, Treatment |
| dual beta lactam therapy: The Antibiotic Paradox Stuart B. Levy, 2013-11-11 The discovery of antibiotics heralded medicine's triumph over previously fatal diseases that once destroyed entire civilizations - thus earning their reputation as miracle drugs. But today, the terrifying reality of antibiotic-resistant bacteria resulting from our widespread misuse of antibiotics forewarns us that the miracle may be coming to an end. The seemingly innocent consumer who demands antibiotics to treat nonbacterial diseases such as the common cold or plays doctor by saving old prescriptions for later use is paving the way for a future of antibiotic failure. What harm can it do? is a popular refrain of people worldwide as they pop another antibiotic pill. Dr. Stuart Levy - the leading international expert on hazards of antibiotic misuse - reveals how this cavalier and naive attitude about the power of antibiotics can have deadly consequences. He explains that we are presently witnessing a massive evolutionary change in bacteria. This build-up of new antibiotic-resistant bacteria in individuals and the environment worldwide is an insidious and silent process. Thus, unwittingly consumers encounter resistant bacteria in their meat, poultry, fish, and vegetables. Unregulated dispensing of antibiotics in poorer countries breeds countless more resistant strains. Since bacteria recognize no geographical boundaries, resistant forms can travel the globe. If this trend continues to grow unchecked, we may someday find that all of our antibiotics are obsolete. Today doctors can no longer expect that their first choice of antibiotic for women's urinary tract infections or children's ear infections will work. Similarly, cancer therapy is rendered useless if patients are unable to fight infections that are sometimes resistant to eight to ten different drugs. In developing countries, people are now dying of previously treatable diseases that are no longer responsive to traditional antibiotics. These problems are just a harbinger of what will come if we do not act now. Dr. Levy, recognized by The New Yorker for his superb contributions to this field, is sending out an urgent message that the world cannot afford to ignore any longer. The goal of this unprecedented investigation into the dangers of antibiotic misuse is to protect the world community from resistant infections and ensure the success of antibiotics for generations to come |
| dual beta lactam therapy: Kucers' The Use of Antibiotics M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, 2017-10-02 Kucers’ The Use of Antibiotics is the definitive, internationally-authored reference, providing everything that the infectious diseases specialist and prescriber needs to know about antimicrobials in this vast and rapidly developing field. The much-expanded Seventh Edition comprises 4800 pages in 3 volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed. Concentrating on the treatment of infectious diseases, the content is divided into four sections - antibiotics, anti-fungal drugs, anti-parasitic drugs, and anti-viral drugs - and is highly structured for ease of reference. Each chapter is organized in a consistent format, covering susceptibility, formulations and dosing (adult and pediatric), pharmacokinetics and pharmacodynamics, toxicity, and drug distribution, with detailed discussion regarding clinical uses - a feature unique to this title. Compiled by an expanded team of internationally renowned and respected editors, with expert contributors representing Europe, Africa, Asia, Australia, South America, the US, and Canada, the Seventh Edition adopts a truly global approach. It remains invaluable for anyone using antimicrobial agents in their clinical practice and provides, in a systematic and concise manner, all the information required when prescribing an antimicrobial to treat infection. |
| dual beta lactam therapy: Growing and Handling of Bacterial Cultures Madhusmita Mishra, 2019-12-04 Growing and Handling of Bacterial Cultures is a collection of reviewed and relevant research chapters, offering a comprehensive overview of recent developments in the field of Life Sciences. The book comprises single chapters authored by various researchers and edited by an expert active in the field. All chapters are complete in itself but united under a common research study topic. This publication aims at providing a thorough overview of the latest research efforts by international authors on Growing and Handling of Bacterial Cultures, and open new possible research paths for further novel developments. |
| dual beta lactam therapy: Infectious Diseases, Microbiology and Virology Luke S. P. Moore, James C. Hatcher, 2019-12-05 A key resource for FRCPath and MRCP trainees, mapped to the current curriculum, using over 300 exam-style Q&A. |
| dual beta lactam therapy: 21st Century Challenges in Antimicrobial Therapy and Stewardship Islam M. Ghazi, Michael J. Cawley, 2020-11-19 21st Century Challenges in Antimicrobial Therapy and Stewardship addresses selected topics that are of importance in the practice of infectious disease management. The text starts by illustrating the global landscape of antimicrobial drug resistance, which influences antimicrobial use and therapeutic decisions in the clinic. The contributors explain the reasons for the spread of antibiotic resistance, the pharmacology of antibiotics of different classes, innovative drug delivery methods which can improve the efficacy and safety of new drug candidates and achieve targeted drug delivery as well as drug resistance monitoring techniques and issues in the practice of antimicrobial stewardship and infection control. Key Features: - 14 organized chapters on several aspects of antimicrobial therapy and stewardship - Introductory knowledge on global antimicrobial trends - Coverage of molecular basis of antimicrobial resistance in gram positive, gram negative and fungal microbes - Focused coverage on new developments in antimicrobial drug development, drug delivery, formulation and diagnostic tools - Information on unmet needs of patients and clinicians, including the treatment of difficult infections - Comprehensive coverage of issues in antimicrobial stewardship 21st Century Challenges in Antimicrobial Therapy and Stewardship brings to readers – healthcare administrators, educators, pharmacists, clinicians and students, alike – the knowledge of the molecular basis of antimicrobial drug therapy, drug resistance in pathogens and current practices in antimicrobial stewardship programs. This knowledge, in turn, fosters an awareness among healthcare industry participants to collaborate in an interprofessional environment to combat multidrug resistance. |
| dual beta lactam therapy: Antibiotic Discovery and Development Thomas J. Dougherty, Michael J. Pucci, 2011-12-18 This volume covers all aspects of the antibiotic discovery and development process through Phase II/III. The contributors, a group of highly experienced individuals in both academics and industry, include chapters on the need for new antibiotic compounds, strategies for screening for new antibiotics, sources of novel synthetic and natural antibiotics, discovery phases of lead development and optimization, and candidate compound nominations into development. Beyond discovery , the handbook will cover all of the studies to prepare for IND submission: Phase I (safety and dose ranging), progression to Phase II (efficacy), and Phase III (capturing desired initial indications). This book walks the reader through all aspects of the process, which has never been done before in a single reference. With the rise of antibiotic resistance and the increasing view that a crisis may be looming in infectious diseases, there are strong signs of renewed emphasis in antibiotic research. The purpose of the handbook is to offer a detailed overview of all aspects of the problem posed by antibiotic discovery and development. |
| dual beta lactam therapy: Infectious Complications in Cancer Patients Valentina Stosor, Teresa R. Zembower, 2014-04-05 While advances in both the treatment of cancer and the management of its complications have led to significant improvement in patient survival, infections remain a significant cause of morbidity and mortality in patients with neo plastic disease. In this patient population, infection risk results from a complex interplay between the host’s underlying immunodeficiencies, local tumor effects and treatment-induced immunosuppression. New chemotherapeutic approaches and antimicrobial prophylaxis and treatment practices continue to shape the spectrum of infections in these patients. Clinicians who treat infections in cancer patients are continually challenged by the emergence of new pathogens and by the increasing antimicrobial resistance of established ones. The aim of this book is to emphasize unique aspects of management of infectious diseases in the cancer patient. With the increasing complexity of this patient population, optimal management requires a multidisciplinary approach and this fact is fully reflected in the contributions, all from recognized authorities in the field. Ultimately, it is hoped that this volume will assist specialists in infectious diseases and haematology/oncology in the diagnosis, management and prevention of infection and optimization of the overall care of patients with malignancies. |
| dual beta lactam therapy: The Pharmacist's Guide to Antimicrobial Therapy and Stewardship Sarah M. Wieczorkiewicz, Carrie Sincak, 2015-12-15 When a patient comes in with a suspected infectious disease, knowledge is power. Now this knowledge is simplified, comprehensive and easy to find. The Pharmacist's Guide to Antimicrobial Therapy and Stewardship puts all the necessary information in one place, including: Evaluating potentially infected patients Identifying the infection's suspected source and related organisms Comparing the range of anti-infectives Knowing the factors that impact treatment Developing an antimicrobial stewardship program A step-wise approach walks logically from overall key concepts to disease- and drug-specific information. Disease states are summarized for easy reference. Tables make it easy to evaluate recommended treatment options. In infectious disease management, when answers are seldom black and white, this guide helps pharmacists make confident decisions. |
| dual beta lactam therapy: Enzymology Primer for Recombinant DNA Technology Hyone-Myong Eun, 1996-06-03 Enzymes are indispensable tools in recombinant DNA technology and genetic engineering. This book not only provides information for enzymologists, but does so in a manner that will also aid nonenymologists in making proper use of these biocatalysts in their research. The Enzymology Primer for Recombinant DNA Technology includes information not usually found in the brief descriptions given in most books on recombinant DNA methodology and gene cloning. - Provides essential basics as well as up-to-date information on enzymes most commonly used in recombinant DNA technology - Presents information in an easily accessible format to serve as a quick reference source - Leads to a better understanding of the role of biocatalysts in recombinant DNA techniques |
| dual beta lactam therapy: The Evolving Threat of Antimicrobial Resistance World Health Organization, 2012 Antibiotic resistance development is a natural process of adaption leading to a limited lifespan of antibiotics. Unnecessary and inappropriate use of antibiotics favours the emergence and spread of resistant bacteria. A crisis has been building up over decades, so that today common and life-threatening infections are becoming difficult or even impossible to treat. It is time to take much stronger action worldwide to avert an ever increasing health and economic burden. A new WHO publication The evolving threat of antimicrobial resistance--Options for action describes examples of policy activities that have addressed AMR in different parts of the world. The aim is to raise awareness and to stimulate further coordinated efforts. |
| dual beta lactam therapy: The Infectious Diseases Consult Handbook Alexander M. Tatara, 2023-09-20 This book is an evidence-based guide for some of the most common consult questions asked of a first-year infectious diseases (ID) fellow working in an academic teaching hospital. Divided into sections based on pathogen and organ system, each covered topic includes reviews of the latest published literature in succinct subsections that can be easily referenced. The book can be read cover to cover as an introduction to clinical infectious diseases through the eyes of an ID fellow or used as a reference in real-time when on clinical service. Written throughout the fellowship of an ID fellow, this handbook shares the quintessential ID topics most commonly encountered on the consult service. From global pandemics to the emergence of drug-resistant superbugs, interest in infectious diseases has never been higher. ID experts weigh in daily on a variety of cases ranging from simple urinary tract infections to devastating sepsis in patients with recent organ transplantation. The ID consult service can be overwhelming given the breadth of infectious diseases that affect our patients. This handbook offers an introductory yet comprehensive resource to professionals, practitioners, students, and fellows. |
| dual beta lactam therapy: Microbial Threats to Health Institute of Medicine, Board on Global Health, Committee on Emerging Microbial Threats to Health in the 21st Century, 2003-08-25 Infectious diseases are a global hazard that puts every nation and every person at risk. The recent SARS outbreak is a prime example. Knowing neither geographic nor political borders, often arriving silently and lethally, microbial pathogens constitute a grave threat to the health of humans. Indeed, a majority of countries recently identified the spread of infectious disease as the greatest global problem they confront. Throughout history, humans have struggled to control both the causes and consequences of infectious diseases and we will continue to do so into the foreseeable future. Following up on a high-profile 1992 report from the Institute of Medicine, Microbial Threats to Health examines the current state of knowledge and policy pertaining to emerging and re-emerging infectious diseases from around the globe. It examines the spectrum of microbial threats, factors in disease emergence, and the ultimate capacity of the United States to meet the challenges posed by microbial threats to human health. From the impact of war or technology on disease emergence to the development of enhanced disease surveillance and vaccine strategies, Microbial Threats to Health contains valuable information for researchers, students, health care providers, policymakers, public health officials. and the interested public. |
| dual beta lactam therapy: Handbook of Sepsis W. Joost Wiersinga, Christopher W. Seymour, 2018-04-13 This practically oriented book provides an up-to-date overview of all significant aspects of the pathogenesis of sepsis and its management, including within the intensive care unit. Readers will find information on the involvement of the coagulation and endocrine systems during sepsis and on the use of biomarkers to diagnose sepsis and allow early intervention. International clinical practice guidelines for the management of sepsis are presented, and individual chapters focus on aspects such as fluid resuscitation, vasopressor therapy, response to multiorgan failure, antimicrobial therapy, and adjunctive immunotherapy. The closing section looks forward to the coming decade, discussing novel trial designs, sepsis in low- and middle-income countries, and emerging management approaches. The book is internatio nal in scope, with contributions from leading experts worldwide. It will be of value to residents and professionals/practitioners in the fields of infectious diseases and internal medicine, as well as to GPs and medical students. |
| dual beta lactam therapy: Pulmonary Disease Diagnosis and Therapy M. I. Gabriel Khan, Joseph P. Lynch, 1997 This handbook also provides extensive coverage of: *Pulmonary function testing; *Asthma, restrictive lung disease; *Bacterial pneumonia; *Acute respiratory distress syndrome; *Acid-base disorders; *Lung cancer and the solitary pulmonary nodule. |
| dual beta lactam therapy: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases John E. Bennett, MD, MACP, Raphael Dolin, MD, Martin J. Blaser, MD, 2014-08-28 After thirty five years, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. John E. Bennett and Raphael Dolin along with new editorial team member Dr. Martin Blaser have meticulously updated this latest edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition helps you identify and treat whatever infectious disease you see. Get the answers to questions you have with more in-depth coverage of epidemiology, etiology, pathology, microbiology, immunology, and treatment of infectious agents than you'll find in any other infectious disease resource. Find the latest diagnoses and treatments for currently recognized and newly emerging infectious diseases, such as those caused by avian and swine influenza viruses. Put the latest knowledge to work in your practice with new or completely revised chapters on influenza (new pandemic strains); new Middle East respiratory syndrome (MERS) virus; probiotics; antibiotics for resistant bacteria; antifungal drugs; new antivirals for hepatitis B and C; Clostridium difficile treatment; sepsis; advances in HIV prevention and treatment; viral gastroenteritis; Lyme disease; Helicobacter pylori; malaria; infections in immunocompromised hosts; immunization (new vaccines and new recommendations); and microbiome. Benefit from fresh perspectives and global insights from an expanded team of international contributors. Find and grasp the information you need easily and rapidly with newly added chapter summaries. These bulleted templates include diagnosis, therapy, and prevention and are designed as a quick summary of the chapter and to enhance relevancy in search and retrieval on Expert Consult. Stay current on Expert Consult with a thorough and regularly scheduled update program that ensures access to new developments in the field, advances in therapy, and timely information. Access the information you need easily and rapidly with new succinct chapter summaries that include diagnosis, therapy, and prevention. Experience clinical scenarios with vivid clarity through a richly illustrated, full-color format that includes 1500 photographs for enhanced visual guidance. |
| dual beta lactam therapy: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose Michael W. Shannon, Stephen W. Borron, Michael J. Burns (MD.), Lester M. Haddad, James F. Winchester, 2007 This edition is a reference for information related to the clinical management of children and adults whose health has been effected or potentially effected by toxic agents, including drugs, environmental threats, and natural toxins. |
| dual beta lactam therapy: Drug Discovery Targeting Drug-Resistant Bacteria Prashant Kesharwani, Sidharth Chopra, Arunava Dasgupta, 2020-05-15 Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included. Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful. |
| dual beta lactam therapy: Irwin and Rippe's Intensive Care Medicine Craig M. Lilly, Richard S. Irwin, Walter A. Boyle, William F. Kelly, 2023-05-25 Covering both the theoretical and practical aspects of critical care,Irwin & Rippe’s Intensive Care Medicine, Ninth Edition, provides state-of-the-art, evidence-based knowledge for specialty physicians and non-physicians practicing in the adult intensive care environment. Drs. Craig M. Lilly, Walter A. Boyle, and Richard S. Irwin, along with a team of expert contributing authors and education expert, William F. Kelly, offer authoritative, comprehensive guidance from an interprofessional, collaborative, educational, and scholarly perspective, encompassing all adult critical care specialties. |
| dual beta lactam therapy: Mechanisms of Catalysis , 1991-01-28 The remarkable expansion of information leading to a deeper understanding of enzymes on the molecular level necessitated the development of this volume which not only introduces new topics to The Enzymes series but presents new information on some covered in Volume I and II of this edition. |
| dual beta lactam therapy: Synthesis of Best-Seller Drugs Ruben Vardanyan, Victor Hruby, 2016-01-07 Synthesis of Best-Seller Drugs is a key reference guide for all those involved with the design, development, and use of the best-selling drugs. Designed for ease of use, this book provides detailed information on the most popular drugs, using a practical layout arranged according to drug type. Each chapter reviews the main drugs in each of nearly 40 key therapeutic areas, also examining their classification, novel structural features, models of action, and synthesis. Of high interest to all those who work in the captivating areas of biologically active compounds and medicinal drug synthesis, in particular medicinal chemists, biochemists, and pharmacologists, the book aims to support current research efforts, while also encouraging future developments in this important field. - Describes methods of synthesis, bioactivity and related drugs in key therapeutic areas - Reviews the main drugs in each of nearly 40 key therapeutic areas, also examining their classification, novel structural features, models of action, and more - Presents a practical layout designed for use as a quick reference tool by those working in drug design, development and implementation |
| dual beta lactam therapy: Evidence-Based Practice of Critical Care E-Book Clifford S. Deutschman, Patrick J. Neligan, 2015-11-26 Evidence-Based Practice of Critical Care, 2nd Edition, presents objective data and expert guidance on managing critically ill patients in unique question-based chapters that focus on best practices. Now thoroughly updated by Drs. Clifford S. Deutschman, Patrick J. Neligan, and nearly 200 critical-care experts, this highly regarded title remains the only book of its kind that provides a comprehensive framework for translating evidence into practice, making it a valuable resource for both residents and practitioners. Tap into the expertise of nearly 200 critical-care experts who discuss the wide variety of clinical options in critical care, examine the relevant research, and provide recommendations based on a thorough analysis of available evidence. Think through each question in a logical, efficient manner, using a practical, consistent approach to available management options and guidelines. Find the information you need quickly with tables that summarize the available literature and recommended clinical approaches. Navigate a full range of challenges from routine care to complicated and special situations. Stay up to date with new issues and controversies such as the redefinition of sepsis • changing approaches to fluid administration • immune suppression in sepsis • monitoring the microcirculation • the long-term sequelae of critical illness • minimizing ventilator associated lung injury • the benefits of evidence-based medicine management guidelines • rapid response teams • and more. Benefit from all-new sections covering persistent critical illness and the role of advanced practice nurses and physician assistants in the ICU. |
| dual beta lactam therapy: Combination Therapy Against Multidrug Resistance Mohmmad Younus Wani, Aijaz Ahmad, 2020-04-30 Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant - Explores strategic methods with investigation of both short- and long-term goals to combat multidrug resistance - Presents a broad scope to understand fully the ways to apply combined therapy to multidrug resistance - Provides an overview of combination therapy, but also includes specific cases such as cancer, tuberculosis, HIV and malaria |
| dual beta lactam therapy: Manual of Childhood Infections Mike Sharland, Andrew Cant, E. Graham Davies, David A. C. Elliman, Susanna Esposito, Delane Shingadia, Adam Finn, 2011-04-07 This manual gives information on the causative organisms, epidemiology and clinical features of all important childhood infections. It includes guidance on the clinical management of the infections and on steps to be taken to prevent future cases. |
| dual beta lactam therapy: Encyclopedia of Molecular Pharmacology Stefan Offermanns, W. Rosenthal, 2008-08-14 An essential text, this is a fully updated second edition of a classic, now in two volumes. It provides rapid access to information on molecular pharmacology for research scientists, clinicians and advanced students. With the A-Z format of over 2,000 entries, around 350 authors provide a complete reference to the area of molecular pharmacology. The book combines the knowledge of classic pharmacology with the more recent approach of the precise analysis of the molecular mechanisms by which drugs exert their effects. Short keyword entries define common acronyms, terms and phrases. In addition, detailed essays provide in-depth information on drugs, cellular processes, molecular targets, techniques, molecular mechanisms, and general principles. |
| dual beta lactam therapy: Antibiotic Resistance: Challenges and Opportunities, An Issue of Infectious Disease Clinics of North America Robert A. Bonomo, Richard R. Watkins, 2016-06-11 For many years, physicians and the public assumed that the discovery of new antimicrobial agents would outpace the ability of bacteria to mutate and develop drug resistance. Yet the development of new antibiotics has not kept up with bacterial evolution, especially since the late 1990’s. At that time a multitude of pharmaceutical companies abandoned antibiotic research because of strong economic disincentives. For example, it is challenging for these companies to recuperate the investment (typically in the hundreds of millions of dollars) made in developing a new antibiotic, which is typically prescribed for a few days, compared to drugs that treat chronic conditions like heart disease or mental illness. This situation has led the U.S. federal government to take a more active lead in addressing antibiotic resistance. Recently, the White House announced an action plan that includes improving surveillance, developing better diagnostic tools, accelerating drug development, and improving global coordination of antibiotic resistance issues. Equally important is the $1.2 billion dollars that has been pledged to fund these efforts. While we await the implementation of new policies, this issue of Infectious Disease Clinics of North America brings together leading authorities in the field of antibiotic resistance who discuss current issues including antibiotic stewardship, the changing role of the microbiology laboratory in determining antibiotic resistance in gram-negative pathogens, the continuing spread of metallo-ß-lactamases, ESBLs and KPCs, antibiotic options for treating resistant gram-negative infections such as colistin and tigecycline, resistance mechanisms and new treatment options for Mycobacterium tuberculosis, emerging resistance mechanisms in aminoglycosides, issues with antibiotic resistance in immunocompromised patients, new ß-lactamase inhibitors in the clinic, and resistance in VRE and Staphylococcus aureus. Additionally, combination therapy for resistant gram-negative infections has been advocated by some authorities and the advantages and disadvantages of this strategy will be reviewed. |
| dual beta lactam therapy: Antimicrobial Resistance World Health Organization, 2014 Summary report published as technical document with reference number: WHO/HSE/PED/AIP/2014.2. |
| dual beta lactam therapy: Renal Fibrosis: Mechanisms and Therapies Bi-Cheng Liu, Hui-Yao Lan, Lin-Li Lv, 2019-08-09 This book systemically presents the latest research on renal fibrosis, covering all the major topics in the field, including the possible mechanisms, biomarkers, and strategies for prevention and treatment of chronic kidney disease (CKD). Due to its high prevalence, CKD represents a huge global economic and social burden. Irrespective of the initial causes, CKD progresses to end stage kidney disease (ESKD) due to renal fibrosis, which is characterized by glomerulosclerosis, tubule atrophy and atresia, and the excessive accumulation of extracellular matrix (ECM) in the kidney. Unfortunately, an estimated 1%-2% of the adult population living with CKD will need renal replacement therapy at some point as a result of ESKD. As such, strategies for preventing or slowing CKD progression to ESKD are of utmost importance, and studies aiming to understand the mechanisms of renal fibrosis have been the focus of intensive research. Recently, novel insights into the pathophysiological processes have furthered our understanding of the pathogenesis of renal fibrosis, and more importantly, promoted studies on the early diagnosis and treatment of CKD. This book draws lessons from the extensive, state-of-the-art research in this field, elaborating the new theories and new techniques to offer readers a detailed and comprehensive understanding of renal fibrosis and as well as inspiration for future research directions. |
Marvel Rivals Console/Controller Settings Guide 2025
Dec 27, 2024 · Aim Response Curve Type: Determines how your controller responds when you tilt your right analog stick. You have a choice between Dual-Zone (the new default Overwatch curve …
Best armour and augments for Dual Guns + Longsword build
Apr 18, 2025 · Tc did specifically mention blossom dance. And resistances aren't important when using ghost walker/factory, which I assume he is given the dual guns. Yup I want to abuse Ghost …
Conditions for Dual Ultimates? - Dragon Ball: Xenoverse 2
As long as the custom partner has the Dual Ultimate equipped, they will use it every so often and then you can do the input for the second part of the attack no matter what you have equipped. …
Can I dual wield? - The Elder Scrolls IV: Oblivion - GameFAQs
Sep 10, 2007 · At stage 25 of The Path of Dawn quest, it is scripted for no apparent reason for Martin Septim to have a Lesser Staff of Lightning removed from his inventory, even though, …
Character Creation - Icewind Dale: Enhanced Edition ... - GameFAQs
Apr 30, 2021 · For two-class combinations, dual-classing from Fighter is slightly better than multiclassing because dual-classing gives Grand Mastery, more HP and faster level gain. …
Resident Evil: Director's Cut Walkthrough & Guide - GameFAQs
Mar 24, 2024 · The Director's Cut is the first version of the original Resident Evil that I had played and the one I like best. While the Dual Shock edition that followed adds functionality to the …
Differences between original and Dual Shock versions?
My bad, in regards to the Ink Ribbons... to be really specific, in both modes of the original Director's Cut and in Arrange Mode in the Dual Shock version, you get 3 ribbons each pickup. It's only in …
Character Creation - Baldur's Gate: Enhanced Edition ... - GameFAQs
Apr 21, 2024 · Multiclass vs. Dual Class There is a subtle distinction between multiclass characters and dual-class characters. The idea of playing an A / B multiclass character (for example, a …
Ideal build for Rush for the first playthrough
For me I'm just going for a dual-wield build. Probably a ninja if I can get the requirements for it down. I was BR25 at The Fallen on PC and I got Rush to Ninja about halfway through. Now that …
Some suggestions after 20+ hours for those still struggling
Oct 26, 2024 · Dual Gunner (Tech): fire-infused attack; Quadrastrike (Tech): high-BP damage (perfect for United Attack) Heeled Sandals (Legs): allows you to use a special kick attack …
Marvel Rivals Console/Controller Settings Guide 2025
Dec 27, 2024 · Aim Response Curve Type: Determines how your controller responds when you tilt your right analog stick. You have a choice between Dual-Zone (the new default Overwatch …
Best armour and augments for Dual Guns + Longsword build
Apr 18, 2025 · Tc did specifically mention blossom dance. And resistances aren't important when using ghost walker/factory, which I assume he is given the dual guns. Yup I want to abuse …
Conditions for Dual Ultimates? - Dragon Ball: Xenoverse 2
As long as the custom partner has the Dual Ultimate equipped, they will use it every so often and then you can do the input for the second part of the attack no matter what you have equipped. …
Can I dual wield? - The Elder Scrolls IV: Oblivion - GameFAQs
Sep 10, 2007 · At stage 25 of The Path of Dawn quest, it is scripted for no apparent reason for Martin Septim to have a Lesser Staff of Lightning removed from his inventory, even though, …
Character Creation - Icewind Dale: Enhanced Edition ... - GameFAQs
Apr 30, 2021 · For two-class combinations, dual-classing from Fighter is slightly better than multiclassing because dual-classing gives Grand Mastery, more HP and faster level gain. …
Resident Evil: Director's Cut Walkthrough & Guide - GameFAQs
Mar 24, 2024 · The Director's Cut is the first version of the original Resident Evil that I had played and the one I like best. While the Dual Shock edition that followed adds functionality to the …
Differences between original and Dual Shock versions?
My bad, in regards to the Ink Ribbons... to be really specific, in both modes of the original Director's Cut and in Arrange Mode in the Dual Shock version, you get 3 ribbons each pickup. …
Character Creation - Baldur's Gate: Enhanced Edition ... - GameFAQs
Apr 21, 2024 · Multiclass vs. Dual Class There is a subtle distinction between multiclass characters and dual-class characters. The idea of playing an A / B multiclass character (for …
Ideal build for Rush for the first playthrough
For me I'm just going for a dual-wield build. Probably a ninja if I can get the requirements for it down. I was BR25 at The Fallen on PC and I got Rush to Ninja about halfway through. Now …
Some suggestions after 20+ hours for those still struggling
Oct 26, 2024 · Dual Gunner (Tech): fire-infused attack; Quadrastrike (Tech): high-BP damage (perfect for United Attack) Heeled Sandals (Legs): allows you to use a special kick attack …
